Stevens First Principles Investment Advisors bought a new stake in Monsanto Co. (NYSE:MON) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 5,245 shares of the company’s stock, valued at approximately $542,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Concert Wealth Management Inc. raised its position in Monsanto by 38.1% in the second quarter. Concert Wealth Management Inc. now owns 9,342 shares of the company’s stock worth $962,000 after buying an additional 2,575 shares in the last quarter. Greenleaf Trust raised its position in Monsanto by 2.2% in the second quarter. Greenleaf Trust now owns 69,883 shares of the company’s stock worth $7,227,000 after buying an additional 1,483 shares in the last quarter. Whittier Trust Co. raised its position in Monsanto by 1.5% in the second quarter. Whittier Trust Co. now owns 5,047 shares of the company’s stock worth $522,000 after buying an additional 75 shares in the last quarter. Quadrant Capital Group LLC raised its position in Monsanto by 0.9% in the second quarter. Quadrant Capital Group LLC now owns 1,858 shares of the company’s stock worth $184,000 after buying an additional 16 shares in the last quarter. Finally, Burke & Herbert Bank & Trust Co. bought a new position in Monsanto during the second quarter worth about $256,000. Institutional investors own 79.02% of the company’s stock.
Shares of Monsanto Co. (NYSE:MON) traded up 0.32% during midday trading on Friday, hitting $103.83. The stock had a trading volume of 1,309,735 shares. The stock has a market capitalization of $45.43 billion, a price-to-earnings ratio of 45.70 and a beta of 1.19. The stock has a 50 day moving average price of $104.88 and a 200-day moving average price of $101.34. Monsanto Co. has a 52 week low of $83.73 and a 52 week high of $114.26.
Monsanto (NYSE:MON) last released its quarterly earnings results on Wednesday, October 5th. The company reported $0.07 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.09. The business had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.38 billion. Monsanto had a return on equity of 46.07% and a net margin of 9.89%. Monsanto’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the prior year, the company earned ($0.19) EPS. Equities research analysts anticipate that Monsanto Co. will post $4.89 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 28th. Investors of record on Friday, October 7th will be given a dividend of $0.54 per share. The ex-dividend date of this dividend is Wednesday, October 5th. This represents a $2.16 dividend on an annualized basis and a yield of 2.09%. Monsanto’s dividend payout ratio (DPR) is presently 71.05%.
A number of research analysts recently issued reports on the company. Zacks Investment Research lowered Monsanto from a “hold” rating to a “strong sell” rating in a research report on Friday. Deutsche Bank AG restated a “buy” rating on shares of Monsanto in a research report on Thursday. Barclays PLC restated a “hold” rating and set a $110.00 price objective on shares of Monsanto in a research report on Thursday. Monness Crespi & Hardt reduced their price objective on Monsanto from $130.00 to $128.00 and set a “buy” rating for the company in a research report on Monday. Finally, Goldman Sachs Group Inc. upgraded Monsanto from a “sell” rating to a “neutral” rating and set a $104.00 price objective for the company in a research report on Tuesday, September 27th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Monsanto currently has a consensus rating of “Buy” and a consensus price target of $114.67.
In related news, COO Brett D. Begemann sold 27,980 shares of the stock in a transaction that occurred on Thursday, July 14th. The stock was sold at an average price of $103.62, for a total transaction of $2,899,287.60. Following the sale, the chief operating officer now directly owns 102,480 shares in the company, valued at approximately $10,618,977.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michael K. Stern sold 12,797 shares of the stock in a transaction that occurred on Wednesday, July 13th. The stock was sold at an average price of $101.77, for a total value of $1,302,350.69. Following the sale, the chief executive officer now owns 21,583 shares in the company, valued at $2,196,501.91. The disclosure for this sale can be found here. Corporate insiders own 0.88% of the company’s stock.
Monsanto Company Profile
Monsanto Company (Monsanto), along with its subsidiaries, is a provider of agricultural products for farmers. The Company provides seeds, biotechnology trait products, herbicides and precision agriculture tools to farmers. The Company operates through two segments: Seeds and Genomics, and Agricultural Productivity.